Selective cytotoxicity of the anti-diabetic drug, metformin, in glucose-deprived chicken DT40 cells

Kei Kadoda1, Takahito Moriwaki1∗, Masataka Tsuda2, Hiroyuki Sasanuma2, Masamichi Ishiai2, Minoru Takata3, Hiroshi Ide4, Shin-ichiro Masunaga1, Shunichi Takeda2, Keizo Tano1*

1 Division of Radiation Life Science, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan,
2 Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan,
3 Department of Late Effects Studies, Radiation Biology Center, Kyoto University, Kyoto, Japan,
4 Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Japan

Abstract

Metformin is a biguanide drug that is widely used in the treatment of diabetes. Epidemiological studies have indicated that metformin exhibits anti-cancer activity. However, the molecular mechanisms underlying this activity currently remain unclear. We hypothesized that metformin is cytotoxic in a tumor-specific environment such as glucose deprivation and/or low oxygen (O2) tension. We herein demonstrated that metformin was highly cytotoxic under glucose-depleted, but not hypoxic (2% O2) conditions. In order to elucidate the underlying mechanisms of this selective cytotoxicity, we treated exposed DNA repair-deficient chicken DT40 cells with metformin under glucose-depleted conditions and measured cellular sensitivity. Under glucose-depleted conditions, metformin specifically killed fancc and fancl cells that were deficient in FANCC and FANCL proteins, respectively, which are involved in DNA interstrand cross-link repair. An analysis of chromosomal aberrations in mitotic chromosome spreads revealed that a clinically relevant concentration of metformin induced DNA double-strand breaks (DSBs) in fancc and fancl cells under glucose-depleted conditions. In summary, metformin induced DNA damage under glucose-depleted conditions and selectively killed cells. This metformin-mediated selective toxicity may suppress the growth of malignant tumors that are intrinsically deprived of glucose.

Introduction

Metformin (1, 1-dimethylbiguanide) is a biguanide drug that is used in the treatment of type II diabetes. Metformin primarily acts in the liver to inhibit gluconeogenesis by reducing hyperglycemia and associated elevations in circulating insulin [1–3]. It is also potentially beneficial for cancer prevention. A number of retrospective studies established a relationship between...
the use of metformin and improved cancer-related mortality. Diabetic patients treated with metformin displayed a 31% lower overall relative risk of cancer and cancer-related mortality than those treated with other therapeutics [4]. Furthermore, metformin has been shown to exhibit selective cytotoxicity during glucose deprivation [5].

Cancer cells in solid tumors are surrounded by an extremely hostile environment that is characterized by glucose deprivation and low oxygen tension (hypoxia) due to compromised vascularization from surrounding normal tissues into the tumor mass [6–8]. This specific microenvironment of tumors represents an attractive target for the development of new anti-tumor drugs. Thus, the selective cytotoxic effects of metformin on malignant cells, but not normal cells may be attributable to the toxicity associated with the cancer-specific microenvironment. In addition, the microenvironment of tumors may modify the activities of other drugs. We previously reported that tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide), which is a well-known hypoxic cytotoxic drug, preferentially induced lethal DNA damage under hypoxic conditions [9]. Thus, the selective toxicity of metformin may be attributable to the tumor-specific microenvironment.

We herein hypothesized that metformin preferentially induces DNA damage under glucose-depleted and/or hypoxic conditions and selectively kills cells. In order to test this hypothesis, we used DNA repair-deficient chicken DT40 cells and examined their sensitivity to metformin. Chicken DT40 cells derived from B lymphocytes exhibit higher gene-targeting efficiency and have provided a unique opportunity for detecting the genotoxicity of chemical compounds using a reverse genetic approach [10]. Since these mutant cell lines are completely isogenic to each other and the parental wild-type cell, there are no concerns regarding the influence of genetic bias on the results obtained.

In the present study, we found that metformin was highly cytotoxic against wild-type cells under glucose-depleted, but not hypoxic (2% O2) conditions. Furthermore, under glucose-depleted conditions, metformin specifically killed fancc and fancl cells deficient in Fanconi anemia (FA)-related FANCC and FANCL proteins, respectively, which are involved in DNA interstrand cross-link (ICL) repair. Furthermore, chromosome breakages were efficiently produced by metformin in fancc and fancl, but not wild-type cells under glucose-depleted conditions. The present results suggest that therapeutic concentrations of metformin induce DNA double-strand breaks (DSBs) in cancer cells in a low glucose microenvironment.

**Materials and methods**

**Cell lines and cell culture**

The gene-disrupted DT40 cells used in this study were generated in the Laboratory of Radiation Genetics, Graduate School of Medicine, Kyoto University and the Laboratory of DNA Damage Signaling, Department of Late Effects Studies, Radiation Biology Center, Graduate School of Medicine, Kyoto University (Kyoto, Japan). The genotypes of all mutant clones were confirmed by Southern blotting, PCR, and Western blotting. Cells were cultured at 39˚C with 5% CO2 in RPMI 1640 medium supplemented 10% fetal bovine serum, 1% chicken serum, 100 U/ml penicillin, 100 U/ml streptomycin, 50 μM β-mercaptoethanol, and 2 mM L-glutamine [11]. Regarding glucose deprivation, cells were incubated in glucose-deprived RPMI 1640 medium (Wako Pure Chemical, Japan) supplemented as described above.

**Measurement of viability following exposure to chemicals**

Colony formation was measured as described previously [12]. Briefly, serially diluted cells were plated in triplicate on 60-mm dishes with 8 ml of DMEM/F-12 containing 1.5% methylcellulose, 2 mM L-glutamine, 15% of FCS, and 1.5% of chicken serum with or without different
concentrations of metformin. After a 24-h incubation, serially diluted cells were plated in triplicate on methylcellulose containing DMEM/F-12 medium. In each experiment, colonies were counted after a 7-day incubation at 39°C. Relative viabilities were measured as N/N₀, where N is the mean number of colonies treated with drugs, and N₀ is that of non-treated controls. We obtained survival curves from a three-parameter logistic curve using the package dose response curve in R [13].

Measurement of chromosomal aberrations

An analysis of chromosomal aberrations was performed as described previously [11]. Briefly, cells were treated for 2.5 h with medium containing 0.1 μg/ml colcemid (Gibco). Harvested cells were incubated in 1 ml of 75 mM KCl at room temperature for 15 min and fixed in a 5-ml freshly-prepared 3:1 mixture of methanol-acetic acid. The cell suspension was dropped onto a slide, which was dried. Slides were stained with 5% Giemsa solution (pH6.4, Nacalai Tesque, Japan) for 8 min. Data are presented as macro chromosomal aberrations per 50 meta-phase spreads.

Statistical analysis

Three independent experiments were performed for each data set, unless stated otherwise. The results obtained are expressed as the mean ± SD, unless stated otherwise. The significance of differences was examined using the Student’s t-test, and p values of <0.05 were considered to be significant. A multiple-comparison one-way ANOVA was performed using Tukey’s test.

Results

Metformin induces DNA damage under glucose-depleted conditions

In order to investigate whether metformin exerts cytotoxicity under glucose-depleted and/or low oxygen tension (2% O₂) conditions, we measured the cellular sensitivity of wild-type DT40 cells to metformin. Cells were treated with various concentrations of metformin in glucose-free media or under 2% O₂ in complete media for 24 h. After the treatment, cells were grown in complete media and cellular sensitivity was measured using a colony formation assay. Metformin was highly cytotoxic under glucose-depleted, but not hypoxic conditions (Fig 1A). This result is consistent with previous findings showing the selective cytotoxicity of metformin when combined with the hypoglycemia-mimicking agent 2-deoxy-D-glucose [5,14]. Thus, glucose deprivation augments the cytotoxic effects of metformin.

FA-related proteins are involved in the repair of DNA damage induced by metformin

In an attempt to elucidate whether metformin induces DNA damage under glucose-depleted conditions, we measured the cytotoxic effects of metformin on a panel of DNA repair-deficient DT40 cells. The DNA repair-deficient mutants used in the present study covered homologous recombination repair (HR), non-homologous end joining (NHEJ), base excision repair (BER), nucleotide excision repair (NER), ICL repair (the FA pathway), the repair of DNA-topoisomerase (Topo) crosslinks, and translesion DNA synthesis (TLS) (Listed in S1 Table). These cells were incubated with metformin in glucose-free media for 24 h, and subsequently incubated in complete media to measure cell survival using a colony formation assay. The concentration of metformin that killed cells to the level of 50% of untreated cells (IC₅₀) was assessed for each mutant (Fig 1B). fancc cells deficient in FANCC showed increased sensitivity to metformin.
under glucose-depleted conditions. FANCC is a component of the core FA complex that is required for the DNA damage-induced mono-ubiquitination of FANCl2 and FANCI.

In order to assess the involvement of FA proteins in counteracting the cytotoxic effects of metformin in more detail, a panel of DT40 cells defective in the FA repair pathway (S2 Table) was treated with metformin in glucose-free media for 24 h and subsequently incubated in complete media to measure cell survival using a colony formation assay. Fig 2A shows the IC50 values of cells deficient in the FA repair pathway. Among the cell lines deficient in the FA repair pathway, one HR-deficient cell line (rad51c) and three FA-deficient cell lines (fancc, fancl, and fanci) were hypersensitive to metformin. Other HR-deficient cell lines (brca1 and brca2) and FA-deficient cell lines (fancg, fancj, fancm, and fancd2) were not sensitive to metformin. The expression of GFP-FANCC and GFP-FANCL in fanc and fancl cells, respectively, restored resistance to metformin (Fig 2B), confirming that FANCC and FANCL were responsible for increased sensitivity in the absence of glucose.

The FA repair pathway is the main repair pathway of ICLs produced by crosslinking agents such as cis-platinum (CDDP) and mitomycin C. In order to identify the type of DNA damage induced by metformin under glucose-depleted conditions, DT40 cells deficient in the FA repair pathway were treated with CDDP and IC50 values were assessed (S1 Fig). All nine FA cell lines tested were sensitive to CDDP. Among fanc cells, the orders of IC50 values for CDDP

Fig 1. Toxicity of metformin and comparison of cellular sensitivities to metformin among various DNA repair-deficient DT40 cell lines under glucose-depleted conditions. (A) Wild-type cells were treated with the indicated doses of metformin for 24 h in complete medium, no glucose medium, or the 2% O2 hypoxic condition with complete medium, and colonies formed on methylcellulose-containing complete media under normal conditions for 7 days. All data represent the mean ± S.D. normalized to cells not treated with metformin from three independent experiments. In each experiment, relative viabilities were measured as N/N0, where N is the mean number of colonies at each dose of metformin in treated cells and N0 is the mean number of colonies in untreated controls; (B) Histograms of the IC50 values of metformin in the wild-type and various DNA repair-deficient cell lines. Cells were treated with metformin under glucose-depleted conditions for 24 h and colonies formed on complete media. All data represent IC50 values ± 95% confidence intervals normalized to cells not treated with metformin from three independent experiments. In each experiment, relative viabilities were measured as N/N0, where N is the mean number of colonies at each dose of metformin-treated cells and N0 is the mean number of colonies in untreated controls. Abbreviations: Wt, wild type; NER, nucleotide excision repair; BER, base excision repair; Topo-DNA, repair of DNA-topoisomerase (Topo) crosslinks; TLS, translation DNA synthesis; NHEJ, non-homologous end joining; HR, homologous recombination repair; FA, FA pathway (ICL repair).

https://doi.org/10.1371/journal.pone.0185141.g001
and metformin were as follows:

\[
\text{IC}_{50} \text{ (CDDP)} : \; \text{wt} > e = m = g > 100 > j = d2 = i = c = l
\]

\[
\text{IC}_{50} \text{ (metformin)} : \; g > e > j = m > d2 = \text{wt} = 100 > i > l > c
\]
Although only three FA cell lines (fancc, fancl, and fanci) were sensitive to metformin, they were also highly sensitive to CDDP. Collectively, these results suggest that although metformin induces DNA damage that is repaired by the FA pathway, this DNA damage may not be canonical ICLs such as those induced by CDDP. Alternatively, the efficacy of ICL introduction by metformin under glucose-depleted conditions was less than that by CDDP, obviating the apparent need for some FA factors.

DT40 tdp cells deficient in tyrosyl-DNA phosphodiesterase 1 (TDP1) were moderately sensitive to metformin under glucose-depleted conditions (Fig 1B). TDP1 is involved in the repair of Topo 1, which is covalently trapped at the 3’ end of DNA, thereby contributing to the repair of DNA-protein crosslinks (DPCs) \[15\]. We also found that parp1 cells deficient in poly(ADP-ribose) ribose polymerase 1 (PARP1) were moderately sensitive to metformin under glucose-depleted conditions (Fig 2C). Furthermore, the tdp1 parp1 double mutant showed an epistatic profile with the corresponding single mutant (Fig 2C). PARP1 catalyzes the addition of poly (ADP-ribose) to various proteins. A previous study reported that TDP1 and PARP1 were epistatic for the repair of trapped Topo1-DNA crosslinks \[16\]. PARP1 was shown to bind the regulatory domain of TDP1, and this coupling stimulated the excision of trapped Topo1-DNA crosslinks by the phosphodiesterase activity of TDP1. These findings clearly demonstrated that PARP1 was a key component for the repair of Topo1-trapped DNA crosslinks \[16\]. Thus, our results obtained with tdp1 and parp1 cells (Fig 2C) suggest that metformin produces DPC-type DNA damage (i.e., trapped Topo 1-DNA crosslinks) under glucose-depleted conditions together with ICL-type DNA damage, which is repaired by the FA pathway. Future studies are needed in order to characterize the DNA lesion(s) induced by metformin under glucose-depleted conditions.

A therapeutic concentration of metformin induces chromosomal aberrations in glucose-depleted fancc and fancl cells

The hypersensitivities of repair-deficient DT40 cells to metformin (Fig 1B) suggest that metformin induces DNA damage under specific physiological conditions, particularly cells deficient in the FA pathway. Previous studies reported that defects in FA proteins markedly increased chromosomal breaks in mitotic chromosome spreads following the exposure of cells to crosslinking agents \[17–19\]. Thus, we analyzed chromosomal breaks in mitotic chromosome spreads following exposure to metformin. Under glucose-depleted conditions, metformin at 13 μM induced chromosome breakages in fancc and fancl DT40 cells, but not wild-type cells (Fig 3A). Furthermore, the expression of GFP-FANCC or GFP-FANCL in fancc or fancl cells reversed the level of chromosomal breaks to that of wild-type cells (Fig 3A), confirming that FANCC and FANCL proteins are required for the repair of DNA damage induced by metformin under glucose-depleted conditions.

Metformin has been widely used to treat type 2 diabetes with proven safety for clinical use. The serum concentration of metformin during clinical treatments is reported to be between 0.1 and 20 μM \[20\]. Therefore, we treated fancc and fancl DT40 cells with lower concentrations of metformin in glucose-free media and analyzed mitotic chromosomal aberrations. As shown in Fig 3B, chromosomal breaks were hardly detected at 0.013 μM of metformin in glucose-depleted fancc and fancl cells. However, chromosomal breaks were detected at 0.13 μM of metformin in glucose-depleted fancc and fancl cells. Thus, clinically relevant concentrations of metformin produce chromosomal breakages in the FA pathway-deficient genetic background, killing cells.

Discussion

Previous studies showed that chronical exposure at high concentrations of metformin may be toxic at physiological concentrations of glucose \[5,14\]. However, the toxic effects of therapeutic
concentrations of metformin remain unclear. We herein provide compelling evidence for the cytotoxicity/genotoxicity of metformin in the absence of glucose. Metformin was highly cytotoxic to DNA repair-deficient fancc and fancl cells and moderately cytotoxic to fanci cells in the absence of glucose. Moreover, metformin induced mitotic chromosomal breaks in fancc and fancl cells, but not wild-type cells under glucose-depleted conditions. These results indicate that metformin is cytotoxic and genotoxic under specific conditions, namely, glucose-free medium. The lack of genotoxicity of metformin has been demonstrated in clinical trials with diabetic patients and healthy control groups. However, the mechanisms by which metformin acquires selective cytotoxicity/genotoxicity in the absence of glucose currently remain unclear.
We herein showed that all nine FA-deficient cell lines tested were sensitive to CDDP, whereas three out of the nine FA-deficient cell lines were sensitive to metformin (Fig 2A and S1 Fig). Thus, metformin may not generate typical ICLs such as those generated by CDDP and mitomycin C and repaired by the canonical FA-repair pathway. For example, previous studies reported that psoralen-induced ICLs were repaired by a DNA glycosylase mediated-pathway that is independent of the canonical FA repair pathway [21,22]. In the case of the DNA glycosylase-mediated pathway, the generation of apurinic/apurimidinic sites by the action of DNA glycosylases may trigger a canonical base excision repair (BER) response involving DNA polymeraseβ. We speculated that the moderate sensitivity observed in polβ cells was partially due to the involvement of BER in the repair of DNA lesions formed by metformin (Fig 1B).

In addition, DT40 cells deficient in either TDP1 or PARP1 showed moderate sensitivity to metformin under glucose-depleted conditions (Fig 2C). These DNA repair factors are involved in the removal of the abortive topoisomerase 1 covalently associated with the 3’-end of single-strand breaks [15,16]. Thus, metformin may induce DPC-type DNA damage (i.e., trapped Topo 1-DNA crosslinks) together with ICL-type DNA damage, which is repaired by the FA pathway under glucose-depleted conditions. For example, endogenous aldehydes generate a number of lethal crosslink products such as ICLs and DPCs [23–26].

In summary, we propose that metformin induces non-canonical ICLs and trapped Topo1 DPCs when glucose is depleted. Since cells present in malignant tumors are deprived of glucose [27], the cytotoxicity/genotoxicity of metformin may play an important role in suppressing the growth of malignant tumors. During the preparation of this manuscript, Grompe’s group reported that metformin delayed the formation of tumors in FA-deficient mice [28]. It is tempting to speculate that metformin selectively killed glucose-deprived tumors in these FA-deficient mice and exhibited protective activity against tumor formation in these mice.

Future studies need to identify the endogenous metabolic products that are cytotoxic and genotoxic and induced by metformin under glucose-depleted conditions. Glucose deprivation causes a marked shift in metabolism and induces oxidative stress, the activation of oncogenes such as c-Myc, and several signaling pathways [27]. Thus, it is not unexpected that metformin, directly and/or indirectly, induces different types of DNA damage in cells with physiological concentrations of glucose. In addition, we successfully detected cytotoxicity/genotoxicity associated with therapeutic concentrations of metformin by measuring cell viability and mitotic chromosomal breaks following the exposure of DT40 cells deficient in the FA pathway to metformin. Even though the cytotoxicity of metformin to wild-type cells under glucose-depleted conditions is not significant, its administration to patients with a FA-deficient background or its combined use with anti-tumor drugs, particularly ICL inducers such as CDDP, needs to be carefully considered [29–31].

Supporting information

S1 Table. DT40 isogenic DNA repair mutant cells used in this study.
(DOCX)

S2 Table. DT40 cells defective in FA repair pathway cell lines used in this study.
(DOCX)

S1 Fig. Histograms of IC50 values of CDDP in the wild-type and various FANC-deficient cell lines. Cells were treated with CDDP in complete media for 24 h and colonies formed on complete media. All data represent IC50 values ± 95% confidence intervals normalized to cells not treated with CDDP from three independent experiments. In each experiment, relative viabilities were measured as N/N0 where N is the mean number of colonies at each dose in
metformin-treated cells and $N_0$ is the mean number of colonies in untreated controls.

(TIF)

Acknowledgments

We are grateful to Dr. Tadayoshi Bessho for his critical reading and helpful comments. We thank to Noriko Tano for her expert secretarial assistance.

Author Contributions

Conceptualization: Shunichi Takeda, Keizo Tano.

Formal analysis: Kei Kadoda, Takahito Moriwaki.

Funding acquisition: Shin-ichiro Masunaga, Keizo Tano.

Investigation: Kei Kadoda, Takahito Moriwaki, Masataka Tsuda, Hiroyuki Sasanuma, Shunichi Takeda, Keizo Tano.

Methodology: Masataka Tsuda, Hiroyuki Sasanuma.

Project administration: Keizo Tano.

Validation: Masamichi Ishiai, Minoru Takata, Hiroshi Ide, Shin-ichiro Masunaga, Shunichi Takeda, Keizo Tano.

Visualization: Kei Kadoda, Takahito Moriwaki.

Writing – original draft: Kei Kadoda.

Writing – review & editing: Masamichi Ishiai, Hiroshi Ide, Shunichi Takeda, Keizo Tano.

References

1. Inzucchi SE, Maggs DG, Spoletti GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338: 867–872. https://doi.org/10.1056/NEJM199803263381303 PMID: 9516221

2. Stumvoll M, Nurjan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333: 550–554. https://doi.org/10.1056/NEJM199508313330903 PMID: 7623903

3. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994; 43: 920–928. https://doi.org/10.2337/diab.43.7.920 PMID: 8013758

4. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer prev res. 2010; 3: 1451–1461. https://doi.org/10.1158/1940-6207.CAPR-10-0157 PMID: 20947488

5. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-ya K, et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 2009; 69: 4225–4234. https://doi.org/10.1158/0008-5472.CAN-08-2689 PMID: 19435925

6. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003; 94: 1021–1028. https://doi.org/10.1111/j.1349-7006.2003.tb01395.x PMID: 14662015

7. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9(4): 539–549. PMCID: PMC2073776 PMID: 13304213

8. Zhu Y, Zhao T, Itasaka S, Zeng L, Yeom CJ, Hirota K, et al. Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells. Oncogene. 2013; 32: 2058–2068. https://doi.org/10.1038/onc.2012.223 PMID: 22710721
Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2015; 75: 4180–4188. https://doi.org/10.1158/0008-5472.CAN-14-3867 PMCID: PMC4514205

Yabe M, Yabe H, Morimoto T, Fukumura A, Ohtsubo K, Koike T, et al. The phenotype and clinical course of Japanese Fanconi anaemia infants is influenced by patient, but not maternal ALDH2 genotype. Br J Haematol. 2016; 175: 457–461. https://doi.org/10.1111/bjh.14243 PMID: 27377053

Hira A, Yabe H, Yoshida K, Okuno Y, Shiraiishi Y, Chiba K, et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood. 2013; 122: 3206–3209. https://doi.org/10.1182/blood-2013-05-507962 PMID: 24037726

Garaycochea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature. 2012; 489: 571–575. https://doi.org/10.1038/nature11368 PMID: 22922648

Rosado IV, Langevin F, Crossan GP, Takata M, Patel KJ. Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nat Struct Mol Biol. 2011; 18: 1432–1434. https://doi.org/10.1038/nsmb.2173 PMID: 22081012

Blackburn RV, Spitz DR, Liu X, Galoforo SS, Sim JE, Ridour LA, et al. Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. Free Radic Biol Med. 1999; 26: 419–430. https://doi.org/10.1016/S0891-5849(98)00217-2 PMID: 9895234

Zhang QS, Tang W, Deater M, Phan N, Marcogliese AN, Li H, et al. Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood. 2016; 128: 2774–2784. https://doi.org/10.1182/blood-2015-11-683490 PMID: 27756748
29. Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 2011; 651:41–50. https://doi.org/10.1016/j.ejphar.2010.11.005 PMID: 21114978

30. Sui X, Xu Y, Wang X, Han W, Pan H, Xiao M. Metformin: A novel but controversial drug in cancer prevention and treatment. Mol Pharm. 2015; 12:3783–3791. https://doi.org/10.1021/acs.molpharmaceut.5b00577 PMID: 26430787

31. Qi X, Xu W, Xie J, Wang Y, Han S, Wei Z, et al. Metformin sensitize the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis. Sci Rep. 2016; 6:35788. https://doi.org/10.1038/srep35788 PMID: 27762347